Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled study of BAY 3401016 in adults with Alport syndrome
jRCT2051250133Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Alport syndrome comparing BAY 3401016 with Placebo (2 arms). Primary endpoint: Urinary albumin creatinine ratio ratio to baseline averaged over weeks 16, 20, and 24. Started Nov 2025; status: active, not recruiting.
02
Drugs
BAY 3401016
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on jRCT2051250133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250133.